TNGX vs. TYRA, ELVN, PLRX, ARCT, ALXO, OPK, AUPH, IRON, NRIX, and SVRA
Should you be buying Tango Therapeutics stock or one of its competitors? The main competitors of Tango Therapeutics include Tyra Biosciences (TYRA), Enliven Therapeutics (ELVN), Pliant Therapeutics (PLRX), Arcturus Therapeutics (ARCT), ALX Oncology (ALXO), OPKO Health (OPK), Aurinia Pharmaceuticals (AUPH), Disc Medicine (IRON), Nurix Therapeutics (NRIX), and Savara (SVRA). These companies are all part of the "pharmaceutical preparations" industry.
Tyra Biosciences (NASDAQ:TYRA) and Tango Therapeutics (NASDAQ:TNGX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.
84.1% of Tyra Biosciences shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 18.4% of Tyra Biosciences shares are owned by company insiders. Comparatively, 6.2% of Tango Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Tango Therapeutics had 12 more articles in the media than Tyra Biosciences. MarketBeat recorded 12 mentions for Tango Therapeutics and 0 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 1.23 beat Tango Therapeutics' score of 0.00 indicating that Tango Therapeutics is being referred to more favorably in the news media.
Tyra Biosciences received 3 more outperform votes than Tango Therapeutics when rated by MarketBeat users. Likewise, 57.69% of users gave Tyra Biosciences an outperform vote while only 54.55% of users gave Tango Therapeutics an outperform vote.
Tyra Biosciences currently has a consensus price target of $22.00, suggesting a potential upside of 52.25%. Tango Therapeutics has a consensus price target of $17.25, suggesting a potential upside of 131.23%. Given Tyra Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Tango Therapeutics is more favorable than Tyra Biosciences.
Tyra Biosciences has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Tango Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500.
Tyra Biosciences has higher earnings, but lower revenue than Tango Therapeutics. Tyra Biosciences is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.
Tyra Biosciences has a net margin of 0.00% compared to Tyra Biosciences' net margin of -278.55%. Tango Therapeutics' return on equity of -30.26% beat Tyra Biosciences' return on equity.
Summary
Tango Therapeutics beats Tyra Biosciences on 9 of the 17 factors compared between the two stocks.
Get Tango Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TNGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tango Therapeutics Competitors List
Related Companies and Tools
